Hi Tech Pharmacal
The 10-second takeaway
For the quarter ended Jan. 31 (Q3), Hi Tech Pharmacal beat expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly. GAAP earnings per share dropped significantly.
Margins contracted across the board.
Hi Tech Pharmacal reported revenue of $64.3 million. The four analysts polled by S&P Capital IQ hoped for revenue of $60.5 million on the same basis. GAAP reported sales were 16% higher than the prior-year quarter's $55.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.43. The four earnings estimates compiled by S&P Capital IQ averaged $0.71 per share. GAAP EPS of $0.43 for Q3 were 46% lower than the prior-year quarter's $0.79 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 51.1%, 420 basis points worse than the prior-year quarter. Operating margin was 13.6%, much worse than the prior-year quarter. Net margin was 9.2%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $65.8 million. On the bottom line, the average EPS estimate is $0.80.
Next year's average estimate for revenue is $238.0 million. The average EPS estimate is $2.39.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 205 members out of 221 rating the stock outperform, and 16 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 46 give Hi Tech Pharmacal a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hi Tech Pharmacal is outperform, with an average price target of $39.00.
- Add Hi Tech Pharmacal to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.